Evidence map›Paper›PMID 26851378›Full record

ArticleJournal of neuropathology and experimental neurology2016

Brain Aggregates: An Effective In Vitro Cell Culture System Modeling Neurodegenerative Diseases.

Misol Ahn, Franck Kalume, Rose Pitstick, Abby Oehler, George Carlson, Stephen J DeArmond

Erratum issuedOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuropathology and experimental neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Misol AhnFrom the Department of Pathology (MA, AO, SJD) and Institute for Neurodegenerative Diseases (MA, SJD), University of California San Francisco, California; Department of Pharmacology, University of Washington, Seattle, Washington (FK); and McLaughlin Research Institute, Great Falls, Montana (RP, GC). mahn@ind.ucsf.edu.
Franck KalumeFrom the Department of Pathology (MA, AO, SJD) and Institute for Neurodegenerative Diseases (MA, SJD), University of California San Francisco, California; Department of Pharmacology, University of Washington, Seattle, Washington (FK); and McLaughlin Research Institute, Great Falls, Montana (RP, GC).
Rose PitstickFrom the Department of Pathology (MA, AO, SJD) and Institute for Neurodegenerative Diseases (MA, SJD), University of California San Francisco, California; Department of Pharmacology, University of Washington, Seattle, Washington (FK); and McLaughlin Research Institute, Great Falls, Montana (RP, GC).
Abby OehlerFrom the Department of Pathology (MA, AO, SJD) and Institute for Neurodegenerative Diseases (MA, SJD), University of California San Francisco, California; Department of Pharmacology, University of Washington, Seattle, Washington (FK); and McLaughlin Research Institute, Great Falls, Montana (RP, GC).
George CarlsonFrom the Department of Pathology (MA, AO, SJD) and Institute for Neurodegenerative Diseases (MA, SJD), University of California San Francisco, California; Department of Pharmacology, University of Washington, Seattle, Washington (FK); and McLaughlin Research Institute, Great Falls, Montana (RP, GC).
Stephen J DeArmondFrom the Department of Pathology (MA, AO, SJD) and Institute for Neurodegenerative Diseases (MA, SJD), University of California San Francisco, California; Department of Pharmacology, University of Washington, Seattle, Washington (FK); and McLaughlin Research Institute, Great Falls, Montana (RP, GC).
University of Washington · US

Funding

Therapeutic effects of ketogenic diet in mouse model of severe myoclonic epilepsyK01NS062862 · NINDS · UNIVERSITY OF WASHINGTON · PI KALUME, FRANCK K · 2009 to 2013
$804k
CNS Stem Cells for neurodegenerative disease researchR21AG044720 · NIA · MC LAUGHLIN RESEARCH INSTITUTE · PI CARLSON, GEORGE A. · 2014 to 2015
$467k
Molecular Mechanisms of Prion Disease with Translation to Novel TherapeuticsK01AG039386 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AHN, MISOL · 2011 to 2015
$446k
NIA NIH HHS K01 AG039386NIA NIH HHS K01AG039386NIA NIH HHS R21AG044720NINDS NIH HHS K01 NS062862
6 · The paper itself

Abstract

Drug discovery for neurodegenerative diseases is particularly challenging because of the discrepancies in drug effects between in vitro and in vivo studies. These discrepancies occur in part because current cell culture systems used for drug screening have many limitations. First, few cell culture systems accurately model human aging or neurodegenerative diseases. Second, drug efficacy may differ between dividing and stationary cells, the latter resembling nondividing neurons in the CNS. Brain aggregates (BrnAggs) derived from embryonic day 15 gestation mouse embryos may represent neuropathogenic processes in prion disease and reflect in vivo drug efficacy. Here, we report a new method for the production of BrnAggs suitable for drug screening and suggest that BrnAggs can model additional neurological diseases such as tauopathies. We also report a functional assay with BrnAggs by measuring electrophysiological activities. Our data suggest that BrnAggs could serve as an effective in vitro cell culture system for drug discovery for neurodegenerative diseases.

Indexed as

Models, BiologicalNeurodegenerative DiseasesAction PotentialsAge FactorsAnimalsBrainCell Culture TechniquesCells, CulturedEmbryo, MammalianFemaleHumansMaleMiceMice, TransgenicNerve NetNeurogliaSodium Channel Blockerstau ProteinsBrain aggregatesDendritic degenerationDrug screeningNeurodegenerationTau.

Identifiers

PMID26851378
PMCPMC4902861
OpenAlexW2339353888

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.